Santos-Briz A, Cañueto J, Barrios B, et al. - In the present study, the researchers sought to evaluate the immunohistochemical (IHC) expression of PD-L1, PD-1, and CTLA-4 in samples of patients with advanced melanoma and determine their prognostic value as predictors of immune checkpoint inhibitors (ICI) response at a university hospital. The expression of PD-L1, PD-1, and CTLA-4 was assessed in pretreatment tumor samples in a series of 35 patients (21 patients treated with nivolumab and 14 patients with ipilimumab in monotherapy). In melanoma patients, nivolumab produces a better response than ipilimumab. Although IHC expression of PDL1 and CTLA-4 is linked to a higher response rate to nivolumab and ipilimumab, respectively, as well as longer progression-free survival, the presence of responder patients with negative expression suggests that these biomarkers are insufficient in clinical practice to identify candidates for ICI.